Cantor Fitzgerald initiated coverage of Trevi Therapeutics (TRVI) with an Overweight rating and $25 price target
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TRVI:
- Trevi Therapeutics Stockholders Approve Key Amendments
- Trevi Therapeutics: Positive Developments and Financial Strength Support Buy Rating
- Trevi Therapeutics Announces Public Offering Pricing
- Trevi Therapeutics 17.4M share Secondary priced at $5.75
- Promising Phase 2b Results for Haduvio in IPF-CC Drive Buy Rating and Highlight Market Potential